Inspired by science,
created for life.

Full-Service Dermatology CRO

Innovaderm shares your mission of developing innovative treatments for patients living with skin diseases. With in-depth therapeutic expertise and our focus on dermatology, we are committed to the clinical development of the next generation of dermatology therapies. We provide comprehensive, full-service contract research organization solutions ranging from single to multicenter clinical trials. By partnering with Innovaderm, you make the choice to collaborate with a human-sized, agile and responsive company.

Discover our CRO solutions

Participate in a study

Do you have a skin condition? Would you like to contribute to the advancement of research? Innovaderm is committed to providing you with the best care during this journey. In exchange for your participation, you will be entitled to some financial compensation. Search for available studies now.

See available studies
Scientific expertise symbol


Innovative therapeutic methods for skin disease symbol



Excellent site relationship with dermatology clinics symbol


Testimonial: Investigator Meeting Organization

“All of you did an amazing job today with the remote IM. You guys were a well-oiled machine and you totally caught me by surprise when you started presenting the slides on the antibody, MoA and protocol. Just amazing… you rehearsed the slides well. From a meeting execution standpoint, you get a 10/10. Looks like the sites were also very engaged and asked a lot of good questions. I sense excitement in their questions, which was superb. Can’t wait for these sites to enroll!”

-Director of Clinical Operations, Biotechnology Company


Driven by Science

Dermatology Focused CRO

Testimonial: Study Management During the Covid-19 Crisis

"I want to express our heartfelt and sincere gratitude for the important and amazing work you continue to carry out for our company.  The impact of the effort in which you are engaged helps maintain our business and cannot be overstated: together we are affecting the lives of patients with serious diseases. In some cases, these patients’ diseases are life threatening and they are counting on the experimental medicines that we are developing together.

These are not normal times and it takes extra effort, planning, and execution to generate the drug product, pre-clinical information, or clinical data necessary to advance our important programs.  We thank you for your extraordinary effort."

-Founder & CEO, Biotechnology Company